Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 16/20 | 0.71 |
| ▸ | CCR3 | P51677 | 16/20 | 0.71 |
| ▸ | CCR1 | P32246 | 2/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | DRD4 | P21917 | 4/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6075260 | 0.93 | HRH1 (0.77) | HRH1CCR3CCR1KCNH2DRD2 | |
| SCHEMBL6075050 | 0.92 | HRH1 (0.75) | HRH1CCR3CCR1KCNH2DRD2 | |
| SCHEMBL6074823 | 0.90 | HRH1 (0.78) | HRH1CCR3CCR1KCNH2DRD2 | |
| SCHEMBL6075302 | 0.89 | HRH1 (0.75) | HRH1CCR3CCR1KCNH2DRD2 | |
| SCHEMBL6075311 | 0.89 | HRH1 (0.75) | HRH1CCR3CCR1KCNH2DRD2 | |
| SCHEMBL6074255 | 0.87 | HRH1 (0.80) | HRH1CCR3CCR1KCNH2DRD2 | |
| Cyclohexane SCHEMBL6598467 | 0.86 | HRH1 (0.81) | HRH1CCR3CCR1KCNH2DRD2 | |
| Cyclopentane SCHEMBL6598773 | 0.86 | HRH1 (0.81) | HRH1CCR3CCR1KCNH2DRD2 | |
| SCHEMBL6598499 | 0.86 | HRH1 (0.81) | HRH1CCR3CCR1KCNH2DRD2 | |
| SCHEMBL6598364 | 0.86 | HRH1 (0.73) | HRH1CCR3CCR1KCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239801-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | claimed |
| EP-1299356-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-02-11 | — | — | EP | claimed |
| US-20030153555-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-14 | — | — | US | claimed |
| EP-1299356-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | claimed |
| WO-2001098272-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-12-27 | — | — | WO | claimed |
| US-7005439-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-02-28 | — | — | US | disclosed |
| US-20050239801-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
| EP-1299356-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-02-11 | — | — | EP | disclosed |
| US-20030153555-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-14 | — | — | US | disclosed |
| EP-1299356-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| WO-2001098272-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153555-A1 | Novel compounds | RPS4Y1, RPS4X, UGT2B7 | HRH1 799/4885CCR3 607/4885CCR1 278/4885 |
| US-20050239801-A1 | Novel compounds | CHRM2, CHRM1, C1R | HRH1 201/4885CCR3 1099/4885CCR1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.